Comparison of the Abbott Architect BRAHMS and the Biomérieux Vidas BRAHMS Procalcitonin Assays.

Journal: The journal of applied laboratory medicine

PMID: 31639727

Abstract

BACKGROUND: Procalcitonin (PCT) is a well-established marker for bacterial infection. Recently the US Food and Drug Administration approved the expanded use of this biomarker to guide clinical decisions for antibiotic treatment in patients with lower respiratory tract infections. Both the Architect BRAHMS PCT (PCT-A) and Vidas BRAHMS PCT (PCT-V) are approved for this indication. The aim of this study is to evaluate analytical performance of PCT-A in comparison to PCT-V.

Authors

Dan Wang

Guangdong Pharmaceutical University Guangzhou Guangdong China.
Brittany Caddell

Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC.
Frederick S Nolte

Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC.
Nikolina Babic

Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC. babic@musc.edu.

Keywords

Anti-Bacterial Agents Antimicrobial Stewardship Bacterial Infections Biomarkers Clinical Decision-Making Humans Immunoassay Limit of Detection Luminescent Measurements Procalcitonin Respiratory Tract Infections Sepsis

External Resources

View on PubMed Access via DOI PubMed (31639727)

Comparison of the Abbott Architect BRAHMS and the Biomérieux Vidas BRAHMS Procalcitonin Assays.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals